The patent covers Cara’s second generation, peripherally-selective kappa opioid receptor agonist compounds.
These compounds include CR845, currently completing a Phase I clinical trial and in development for injectable and oral delivery for the treatment of acute and chronic pain of visceral, inflammatory and neuropathic origin, and for the treatment of pruritis, a common disorder associated with several diseases and conditions.